PQA uses a systematic, transparent, and consensus-based process to conceptualize, specify, test, and endorse quality measures. Following endorsement by PQA’s membership, PQA measures can be implemented into various quality programs, including those maintained by the Centers for Medicare & Medicaid Services (CMS). Many PQA measures are used in CMS Quality Programs to evaluate safe and appropriate medication use among beneficiaries.
PQA has appointed individuals from member organizations to serve on the 2023 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
PQA follows a systematic, transparent, and consensus-based process in the development and maintenance of measures. This process ensures that PQA measures are relevant and continue to support improvement in health care.
The Pharmacy Quality Alliance (PQA) has developed a new health plan performance measure focused on medication adherence, Proportion of Days Covered Composite (PDC-CMP). PQA is actively soliciting feedback on this measure via a public comment period which opened on October 3 and will close on October 24, 2022. Stakeholders are invited to provide comments.
PQA has appointed 15 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specification for a health plan performance measure concept: COPD (chronic obstructive pulmonary disease) Treatment Ratio (CTR).
PQA, the Pharmacy Quality Alliance, has begun developing a health plan performance measure for chronic obstructive pulmonary disease (COPD).
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. However, the measurement lifecycle does not end when a measure is endorsed.
Quality measures are standards for measuring the performance of health care providers to care for patients and populations. PQA develops and stewards measures focused on medication use.
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
PQA has appointed 17 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specifications for a health plan measure concept: Proportion of Days Covered (PDC) Composite.
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
PQA has published the 2022 PQA Measure Manual and Value Sets. The PQA Measure Manual includes detailed narrative specifications for PQA measures, which are needed to implement the measures accurately and appropriately. PQA Value Sets, which include National Drug Codes (NDCs), are required to calculate PQA measures as specified.
The Pharmacy Quality Alliance (PQA) seeks interested pharmacy and payer partners to participate in proof-of-concept pilots to implement high priority blood pressure and hemoglobin A1c measure concepts in value-based payment arrangements (VBAs).
Prescription opioid-related deaths are one of the leading preventable public health problems. High-risk prescribing practices have contributed to the opioid overdose epidemic. These include overlapping opioid and benzodiazepine prescriptions, prescribing high-dose opioids and using multiple prescribers or pharmacies for opioid prescriptions.
Concepts Could Be Used in Payer-Pharmacy Value-Based Arrangements
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
This fall and into 2022, there are numerous opportunities for PQA members to participate in our measure development process. As a consensus-based and member-driven organization, this is the moment for you and your organization to inform and influence decisions on measures across the development and stewardship continuum. Here's what's coming up soon. Information on each of these will be emailed to members as we get closer to the opportunity.
PQA endorsed two new diabetes-focused health plan performance measures in December 2020. More than 34 million Americans have diabetes, according to the Centers for Disease Control and Prevention. These measures will help evaluate the quality of care for a disease that annually costs America $327 billion.
